A postal strike in Canada disproportionately threatens the lifeblood of Canadian charities, especially health charities, by blocking trusted fundraising channels and cutting off access to essential ...

Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug Administration (FDA) has ...

Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis ...

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by Faraday ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, will host an Investor Day today where it will highlight ...

Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2 clinical trial in patients with cognitive impairment associated ...

-- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 Trial of RE104 in Postpartum Depression (PPD) in 2026 and RECLAIM Phase 2 Trial in Generalized Anxiety ...

Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network ...

The Type C meeting represents a formal opportunity for Merakris to engage with the FDA under its active Investigational New Drug (IND) application for the treatment of venous leg ulcers. The meeting ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company ...

The second annual Drug Channels Leadership Forum will gather the U.S. pharmaceutical ecosystem’s top leaders, innovators and policy makers to explore the most pressing strategic challenges and ...

ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized.